Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases-Reference-Cited by-同舟云学术

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Published:2008-05-01 Issue:9 Volume:14 Page:2717-2725
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Heinrich Michael C.,Joensuu Heikki,Demetri George D.,Corless Christopher L.,Apperley Jane,Fletcher Jonathan A.,Soulieres Denis,Dirnhofer Stephan,Harlow Amy,Town Ajia,McKinley Arin,Supple Shane G.,Seymour John,Di Scala Lilla,van Oosterom Allan,Herrmann Richard,Nikolova Zariana,McArthur and Grant

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New clinical trial design borrowing information across patient subgroups based on fusion-penalized regression models;Statistical Methods in Medical Research;2024-08-19

2. Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO);Frontiers in Neurology;2024-08-13

3. Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine;JCO Precision Oncology;2024-07

4. Biomarker-driven basket trial designs: origins and new methodological developments;Journal of Biopharmaceutical Statistics;2024-06-04

5. Functional Classification of Fusion Proteins in Sarcoma;Cancers;2024-03-29